» Articles » PMID: 36583743

Neuropeptide Y and Its Receptors in Prostate Cancer: Associations with Cancer Invasiveness and Perineural Spread

Overview
Specialty Oncology
Date 2022 Dec 30
PMID 36583743
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Neuropeptide Y (NPY) is a pleiotropic peptide, which is involved in many biological mechanisms important in regulation of cell growth and survival. The aim of this study was a comprehensive analysis of the NPY system in prostate pathology.

Methods: The study was based on immunohistochemical analysis of NPY and its receptors, Y1R, Y2R and Y5R, in tissue samples from benign prostate (BP), primary prostate cancer (PCa) and PCa bone metastases. Tissue microarray (TMA) technique was employed, with analysis of multiple cores from each specimen. Intensity of the immunoreactivity and expression index (EI), as well as distribution of the immunostaining in neoplastic cells and stromal elements were evaluated. Perineural invasion (PNI) and extraprostatic extension (EPE) were areas of special interests. Moreover, a transwell migration assay on the LNCaP PCa cell line was used to assess the chemotactic properties of NPY.

Results: Morphological analysis revealed homogeneous membrane and cytoplasmic pattern of NPY staining in cancer cells and its membrane localization with apical accentuation in BP glands. All elements of the NPY system were upregulated in pre-invasive prostate intraepithelial neoplasia, PCa and metastases. EI and staining intensity of NPY receptors were significantly higher in PCa then in BP with correlation between Y2R and Y5R. The strength of expression of the NPY system was further increased in the PNI and EPE areas. In bone metastases, Y1R and Y5R presented high expression scores.

Conclusion: The results of our study suggest that the NPY system is involved in PCa, starting from early stages of its development to disseminated states of the disease, and participates in the invasion of PCa into the auto and paracrine matter.

Citing Articles

Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.

Chambers C, Watakul S, Schofield P, Howell A, Zhu J, Tran A Sci Adv. 2025; 11(11):eadq4416.

PMID: 40073121 PMC: 11900870. DOI: 10.1126/sciadv.adq4416.


STModule: identifying tissue modules to uncover spatial components and characteristics of transcriptomic landscapes.

Wang R, Qian Y, Guo X, Song F, Xiong Z, Cai S Genome Med. 2025; 17(1):18.

PMID: 40033360 PMC: 11874447. DOI: 10.1186/s13073-025-01441-9.


Neuropeptide Y in cancer-biological functions and potential clinical implications.

Sigorski D, Sejda A, Abualsaud N, Krawczyk E, Izycka-Swieszewska E, Kitlinska J Cancer Metastasis Rev. 2025; 44(1):21.

PMID: 39760953 PMC: 11703900. DOI: 10.1007/s10555-024-10237-z.


Higher Preoperative Serum Neuropeptide Y Concentration May Be Associated with a Better Prognosis After Surgery for Colorectal Cancer.

Budzynski J, Czarnecki D, Ziolkowski M, Szukay B, Mysiak N, Staniewska A Nutrients. 2024; 16(22).

PMID: 39599612 PMC: 11597490. DOI: 10.3390/nu16223825.


Remarks on Selected Morphological Aspects of Cancer Neuroscience: A Microscopic Photo Review.

Izycka-Swieszewska E, Gulczynski J, Sejda A, Kitlinska J, Galli S, Rogowski W Biomedicines. 2024; 12(10).

PMID: 39457647 PMC: 11505290. DOI: 10.3390/biomedicines12102335.


References
1.
Park Y, Jeong C, Lee S . A comprehensive review of neuroanatomy of the prostate. Prostate Int. 2014; 1(4):139-45. PMC: 3879050. DOI: 10.12954/PI.13020. View

2.
Salido M, Vilches J, Lopez A, Roomans G . Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines. Cancer. 2002; 94(2):368-77. DOI: 10.1002/cncr.10227. View

3.
Kristensen G, Roder M, Drimer Berg K, Elversang J, Iglesias-Gato D, Moreira J . Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer. APMIS. 2018; 126(10):804-813. DOI: 10.1111/apm.12886. View

4.
Senga S, Grose R . Hallmarks of cancer-the new testament. Open Biol. 2021; 11(1):200358. PMC: 7881179. DOI: 10.1098/rsob.200358. View

5.
Magnon C, Hall S, Lin J, Xue X, Gerber L, Freedland S . Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341(6142):1236361. DOI: 10.1126/science.1236361. View